Physician

Michael M. Garcia, M.D.

According to 2025 Medicare claims, Michael Garcia, M.D. (NPI: 1083708762) practices hematology/oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Walker, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35501-8908.

Garcia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 637 traditional Medicare patients, billed 173,883 HCPCS/CPT codes, and received $3,169,490 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,249 prescription claims across 438 beneficiaries totaling $4,473,062 in drug costs, led by Xtandi (Enzalutamide). DME data shows 102 claims. Open Payments data shows 157 records totaling $3,113. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,067,508 to $3,169,490. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,444 to $510.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	663	103,593	$1,067,508
2016	661	254,085	$1,822,845
2017	549	279,460	$2,746,583
2018	641	225,595	$2,799,216
2019	529	179,303	$2,753,399
2020	525	265,777	$3,578,515
2021	552	276,064	$4,617,854
2022	661	262,659	$4,509,974
2023	671	226,355	$3,693,374
2024	637	173,883	$3,169,490

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	426	3,029	$3,654,008
2016	420	2,946	$3,072,792
2017	389	2,788	$2,532,434
2018	376	2,468	$2,951,873
2019	354	2,409	$2,263,279
2020	354	2,546	$2,689,155
2021	413	2,570	$3,650,132
2022	397	2,294	$3,311,662
2023	390	2,133	$4,082,556
2024	438	2,249	$4,473,062

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	239	$105,635
2016	38	198	$102,445
2017	11	104	$33,316
2018	N/R	68	$12,181
2019	N/R	68	$5,361
2020	N/R	12	$637
2021	N/R	91	$5,853
2022	N/R	105	$2,643
2023	N/R	89	$12,363
2024	N/R	102	$2,208

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	303	666	$90
82728	Ferritin (blood protein) level	175	310	$13
80053	Blood test, comprehensive group of blood chemicals	561	1,688	$10
36415	Insertion of needle into vein for collection of blood sample	542	1,556	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	535	1,696	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	122	3,780	$1,265,563
Kisqali	Ribociclib Succinate	47	1,316	$763,373
Ibrance	Palbociclib	23	644	$297,618
Imbruvica	Ibrutinib	24	720	$255,409
Lenalidomide	Lenalidomide	17	476	$245,473

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	46	$1,274
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$508
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	28	$426

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	157	$3,113	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael M. Garcia, M.D.?

Tedicare shows public-source Medicare data for Michael M. Garcia, M.D. (NPI 1083708762), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael M. Garcia, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael M. Garcia, M.D.?

Michael M. Garcia, M.D. is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Michael M. Garcia, M.D. have Open Payments data?

Michael M. Garcia, M.D. has 157 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.